News

News

December 10, 2015

IMMUNOMEDICS REPORTS CONTINUING POSITIVE RESULTS WITH SACITUZUMAB GOVITECAN IN HEAVILY PRE-TREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER PATIENTS

December 7, 2015

IMMUNOMEDICS REPORTS INITIAL RESULTS OF A PHASE I FIRST-IN-MAN STUDY WITH IMMU-114 IN HEMATOLOGIC MALIGNANCIES

December 3, 2015

IMMUNOMEDICS TO PARTICIPATE IN THE 26TH ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE

December 2, 2015

IMMUNOMEDICS ANNOUNCES VOTING RESULTS FROM 2015 ANNUAL MEETING OF STOCKHOLDERS

December 1, 2015

IMMUNOMEDICS TO PRESENT FIRST CLINICAL RESULTS WITH ANTI-HLA-DR ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES AT THE 2015 ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

November 9, 2015

IMMUNOMEDICS REPORTS IMPROVED PROGRESSION-FREE SURVIVAL RESULTS WITH SACITUZUMAB GOVITECAN IN TRIPLE-NEGATIVE BREAST CANCER

November 9, 2015

IMMUNOMEDICS ANNOUNCES SACITUZUMAB GOVITECAN IS SYNERGISTIC WITH CHEMOTHERAPEUTICS THAT TARGET CELL DIVISION IN TRIPLE-NEGATIVE BREAST CANCER

November 4, 2015

IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2016 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

October 29, 2015

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST QUARTER FISCAL 2016 FINANCIAL RESULTS

October 19, 2015

IMMUNOMEDICS REPORTS DURABLE RESPONSES IN PATIENTS WITH ADVANCED SOLID CANCERS AFTER THERAPY WITH SACITUZUMAB GOVITECAN

September 8, 2015

IMMUNOMEDICS REPORTS INTERIM PHASE 2 RESULTS WITH SACITUZUMAB GOVITECAN IN LUNG CANCERS

September 2, 2015

IMMUNOMEDICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

August 19, 2015

IMMUNOMEDICS ANNOUNCES FISCAL 2015 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

August 19, 2015

IMMUNOMEDICS APPOINTS ARTHUR S. KIRSCH AS DIRECTOR

August 18, 2015

IMMUNOMEDICS EXTENDS U.S. PATENT PROTECTION FOR ANTIBODY-DRUG CONJUGATE PROGRAM TO 2033

August 13, 2015

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FOURTH QUARTER AND FISCAL YEAR 2015 FINANCIAL RESULTS

August 4, 2015

IMMUNOMEDICS ANNOUNCES ORPHAN DRUG DESIGNATION FOR VELTUZUMAB FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA

June 2, 2015

IMMUNOMEDICS REPORTS LABETUZUMAB GOVITECAN IS ACTIVE IN RELAPSED METASTATIC COLORECTAL CANCER

June 2, 2015

IMMUNOMEDICS ANNOUNCES DURABLE RESPONSES IN METASTATIC LUNG CANCER PATIENTS TREATED WITH SACITUZUMAB GOVITECAN

June 1, 2015

IMMUNOMEDICS REPORTS PROMISING RESULTS WITH SACITUZUMAB GOVITECAN IN PATIENTS WITH METASTATIC GASTROINTESTINAL CANCERS

June 1, 2015

IMMUNOMEDICS REPORTS COMPLETE RESPONSES IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER AFTER SACITUZUMAB GOVITECAN TREATMENT

May 26, 2015

IMMUNOMEDICS TO PRESENT AT JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE

May 15, 2015

IMMUNOMEDICS AWARDED FAST TRACK DESIGNATION BY FDA FOR SACITUZUMAB GOVITECAN FOR NON-SMALL CELL LUNG CANCER THERAPY

May 14, 2015

IMMUNOMEDICS ANNOUNCES FIVE PRESENTATIONS AT 2015 ASCO FOCUSING ON ANTIBODY-DRUG CONJUGATE PROGRAMS

May 12, 2015

IMMUNOMEDICS EXTENDS U.S. PATENT PROTECTION FOR SACITUZUMAB GOVITECAN TO 2033

May 6, 2015

IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2015 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

April 30, 2015

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER FISCAL 2015 FINANCIAL RESULTS

April 20, 2015

PATIENTS WITH ADVANCED BREAST, LUNG, ESOPHAGEAL, AND COLORECTAL CANCERS RESPOND TO IMMUNOMEDICS’ NOVEL ANTIBODY-DIRECTED CHEMOTHERAPY AFTER FAILING MULTIPLE PRIOR STANDARD TREATMENTS

April 6, 2015

IMMUNOMEDICS TO PROVIDE UPDATE ON SACITUZUMAB GOVITECAN FOR THE THERAPY OF SOLID CANCERS

February 19, 2015

IMMUNOMEDICS PRESENTS UPDATED RESULTS WITH SACITUZUMAB GOVITECAN IN LUNG CANCER

February 12, 2015

IMMUNOMEDICS ANNOUNCES COMPLETION OF OFFERING OF $85 MILLION OF 4.75% CONVERTIBLE SENIOR NOTES DUE 2020

February 5, 2015

IMMUNOMEDICS ANNOUNCES PRICING OF OFFERING OF $85 MILLION OF 4.75% CONVERTIBLE SENIOR NOTES DUE 2020

February 4, 2015

IMMUNOMEDICS ANNOUNCES PROPOSED OFFERING OF $85 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2020

February 4, 2015

IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2015 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

February 3, 2015

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR SECOND QUARTER FISCAL 2015 FINANCIAL RESULTS

January 29, 2015

IMMUNOMEDICS ANNOUNCES DISMISSAL OF PUTATIVE CLASS ACTION LAWSUIT

January 20, 2015

IMMUNOMEDICS REPORTS PHASE 1/2 RESULTS WITH SACITUZUMAB GOVITECAN (IMMU-132) IN PATIENTS WITH METASTATIC GASTROINTESTINAL CANCERS

January 6, 2015

IMMUNOMEDICS APPOINTS DR. FRANCOIS WILHELM CHIEF MEDICAL OFFICER

January 5, 2015

IMMUNOMEDICS AWARDED FAST TRACK DESIGNATION BY FDA FOR SACITUZUMAB GOVITECAN (IMMU-132) FOR TRIPLE-NEGATIVE BREAST CANCER THERAPY